Pik3ca - phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 170911

About Pik3ca

Primary_assembly 2: 115,174,984-115,249,032 forward strand.mRatBN7.2:CM026975.1

This gene has 1 transcript (splice variant), 275 orthologues, 9 paralogues and is associated with 111 phenotypes. Biased expression in Thymus (RPKM 217.1), Lung (RPKM 214.6) and 9 other tissues.

Summary

Enables 1-phosphatidylinositol-3-kinase activity. Involved in several processes, including positive regulation of smooth muscle cell proliferation; response to dexamethasone; and response to leucine. Part of phosphatidylinositol 3-kinase complex. Biomarker of autosomal recessive polycystic kidney disease. Human ortholog(s) of this gene implicated in several diseases, including CLOVES syndrome; Cowden syndrome 5; breast Cancer (multiple); cutaneous Paget's disease; and gastrointestinal system Cancer (multiple). Orthologous to human PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha). [provided by Alliance of Genome Resources, Apr 2022]

Pik3ca Products (1)

mRNA Protein Name
NM_133399.3 NP_596890.2 phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables 1-phosphatidylinositol-3-kinase activity IDA
IDA: Inferred from direct assay
12882977 RGD
enables protein binding IPI
IPI: Inferred from physical interaction
14724584 RGD
Biological Process GO Annotation Evidence References Source
involved in negative regulation of gene expression IGI
IGI: Inferred from genetic interaction
28947594 RGD
involved in phosphatidylinositol phosphate biosynthetic process IDA
IDA: Inferred from direct assay
12882977 RGD
involved in positive regulation of smooth muscle cell proliferation IMP
IMP: Inferred from mutant phenotype
25908763 RGD
involved in response to L-leucine IEP
IEP: Inferred from expression pattern
24124592 RGD
involved in response to activity IEP
IEP: Inferred from expression pattern
23812090 RGD
involved in response to butyrate IEP
IEP: Inferred from expression pattern
24124592 RGD
involved in response to dexamethasone IEP
IEP: Inferred from expression pattern
24124592 RGD
involved in response to muscle inactivity IEP
IEP: Inferred from expression pattern
24124592 RGD
Cellular Component GO Annotation Evidence References Source
part of phosphatidylinositol 3-kinase complex IDA
IDA: Inferred from direct assay
12882977 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Pik3ca Protein Structure

PI3K_p85B

PI3K_p85B: pfam02192 (31 - 106)

PI3K_rbd

PI3K_rbd: smart00144 (172 - 291)

C2_PI3K_class_I_alpha

C2_PI3K_class_I_alpha: cd08398 (324 - 483)

PI3Ka_I

PI3Ka_I: cd00872 (524 - 695)

PI3Kc_IA_alpha

PI3Kc_IA_alpha: cd05175 (694 - 1063)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1000
  • 1068 a.a.
Protein Preferred Names Protein Names

phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • PI3-kinase subunit alpha

  • PI3K-alpha

  • PI3Kalpha

  • p110alpha

  • phosphatidylinositol 3-kinase, catalytic, alpha polypeptide

  • phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha

  • phosphoinositide-3-kinase catalytic alpha polypeptide

  • ptdIns-3-kinase subunit alpha

  • ptdIns-3-kinase subunit p110-alpha

  • serine/threonine protein kinase PIK3CA

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-15244 Alpelisib 99.95% Yes
HY-15244A Alpelisib hydrochloride 99.55% Yes
HY-15244R Alpelisib (Standard) 99.86% Unkown

Clinical Phase

Bioactive Molecules (9)
Cat. No. Product Name Effect
Purity Phase
HY-153306 Zovegalisib Inhibitor 98.80% Phase 3
HY-13898 Taselisib Inhibitor 99.75% Phase 3
HY-108232 MK-2206 99.72% Phase 2
HY-10358 MK-2206 dihydrochloride 99.99% Phase 1
HY-100886 BAY1082439 99.35% Phase 1
HY-137458A Vevorisertib trihydrochloride Inhibitor 98.05% Phase 1
HY-15466 Izorlisib 99.01% Phase 1
HY-126077 MTI-31 Inhibitor 99.92% Phase 1
HY-10358R MK-2206 dihydrochloride (Standard) / Phase 1

Pre-clinical Phase

Bioactive Molecules (13)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-137458 Vevorisertib Inhibitor 98.03% Unkown
HY-137849 RK-582 Inhibitor 98.05% Unkown
HY-RS10523 PIK3CA Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-100424 PI3K-IN-63 Inhibitor / Unkown
HY-138302 PF-06862309 / Unkown
HY-172964 KIM-161 / Unkown
HY-183285 PI3Kα-IN-32 Inhibitor / Unkown
HY-183770 LCI40 Inhibitor / Unkown
HY-N12726 Halociline Inhibitor / Unkown
HY-RS10524 Pik3ca Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS10525 Pik3ca Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-116191 WJD008 Inhibitor / Unkown
HY-15466A Izorlisib methanesulfonate / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Pik3ca NCBI NCBI:5290